Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
U32 CAR-T for Relapsed/Refractory Acute Myeloid Leukemia
NCT07036250Phase 2Recruiting
- Sponsor
- Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd.
- Start
- Jul 2025
- Primary completion
- Dec 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of U32 CAR-T in acute myeloid leukemia (AML), sponsored by Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd.. Started Jul 2025; status: recruiting.
02
Drugs
U32 CAR-T
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07036250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07036250.